Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation. Penumbra stockholders, including employees, are expected to receive $374 per share of Penumbra common stock in a mix of cash and Boston Scientific stock.
The transaction is expected to close in 2026, subject to Penumbra stockholder approval, required regulatory approvals and other customary closing conditions. After closing, Penumbra will become a standalone group within Boston Scientific, and Penumbra’s CEO is expected to join the Boston Scientific board.
Penumbra tells employees there are no immediate changes to day-to-day roles or reporting. Unvested restricted stock units are expected to vest at closing and convert into the same cash/stock mix, and existing employee stock purchase plans will continue through the current purchase period.
Boston Scientific Corporation has executed a definitive agreement to acquire Penumbra, Inc., with the transaction subject to specified terms and closing conditions in the merger agreement. The companies issued a joint press release and Boston Scientific scheduled a same-day conference call and posted an investor presentation to explain the proposed acquisition and its expected impact.
The report emphasizes that many statements about the transaction, its benefits, timing, integration, and future financial and business performance are forward-looking and subject to numerous economic, regulatory, operational, and integration risks, including required regulatory approvals and the possibility the transaction may be delayed or not close. Boston Scientific will file a Form S-4 with a joint proxy statement/prospectus so Penumbra stockholders can review detailed terms before voting.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger, after which Penumbra will become a wholly owned subsidiary and its shares will be delisted from the NYSE. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock. The deal requires approval by Penumbra stockholders, antitrust clearances in the U.S. and other jurisdictions, an effective Form S-4 for Boston Scientific shares, and NYSE listing approval for those shares. The merger agreement includes a $525 million termination fee payable by Penumbra in certain circumstances and a $900 million reverse termination fee payable by Boston Scientific if antitrust-related conditions are not met despite other conditions being satisfied.
Penumbra, Inc. agreed to be acquired by Boston Scientific Corporation through a cash-and-stock merger where Penumbra will become a wholly owned subsidiary. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific common shares, with elections subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock.
The deal requires approval by a majority of Penumbra’s voting shares, antitrust and other regulatory clearances, effectiveness of Boston Scientific’s Form S-4, and NYSE listing approval for the stock consideration. Either side may owe a termination fee under certain conditions, including $525 million payable by Penumbra and $900 million payable by Boston Scientific if specified antitrust-related conditions are not met. If the merger closes, Penumbra’s stock will be delisted and deregistered, and the companies have issued and plan further SEC filings and proxy materials describing the transaction.
Penumbra Inc. director Harpreet Grewal reported a small insider sale of common stock. On January 6, 2026, Grewal sold 186 shares of Penumbra common stock at a price of $312.64 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Grewal directly beneficially owned 8,230 shares of Penumbra common stock.
Penumbra Inc. director Thomas C. Wilder reported a small sale of company stock. On 01/02/2026, he sold 186 shares of Penumbra common stock at a price of $310.72 per share, coded as a sale transaction. Following this trade, he no longer holds shares directly but continues to beneficially own 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
The filing notes that the sale was carried out under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to predetermined instructions.
Penumbra, Inc. insider Harpreet Grewal has filed a notice of proposed sale under Rule 144 for 186 shares of common stock, with an aggregate market value of 58,151.04. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE around January 6, 2026, and Penumbra has 39,162,177 shares of common stock outstanding.
The 186 shares to be sold were acquired as a stock award from Penumbra on December 31, 2025. Over the prior three months, the same seller disposed of 186 shares on November 4, 2025 for 42,329.88 and 100 shares on December 2, 2025 for 29,298.00. By signing the notice, the seller represents that they do not know of any material adverse, nonpublic information about Penumbra’s operations.
A holder of PEN common stock has filed a notice to potentially sell shares under Rule 144. The filing covers the planned sale of 186 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an indicated aggregate market value of $57,793.92. The issuer had 39,162,177 shares outstanding at the time referenced. The shares to be sold were acquired as restricted stock from the issuer on 12/31/2025, with payment also dated 12/31/2025.
Penumbra Inc's chief financial officer, Maggie Yuen, reported a tax-related share withholding tied to her equity compensation. On 12/15/2025, 565 shares of Penumbra common stock were withheld by the company at a price of $309.15 per share, identified with transaction code F for tax withholding.
After this transaction, Yuen beneficially owned 16,006 Penumbra shares, some of which remain subject to vesting. The total includes 15 shares purchased under Penumbra's Employee Stock Purchase Plan on November 19, 2025. The filing characterizes the withholding as satisfying tax obligations arising from the vesting of restricted stock units previously granted to her.
Penumbra’s chief accounting officer, Lambert Shiu, reported an insider transaction involving 300 shares of common stock on 12/15/2025. The 300 shares were withheld by the company to cover tax withholding obligations triggered by the vesting of restricted stock units previously granted to him.
After this transaction, Shiu beneficially owns 35,285 Penumbra common shares directly, with a portion of these shares still subject to vesting and including 20 shares purchased under the company’s Employee Stock Purchase Plan on November 19, 2025. He also indirectly owns 300 shares held in his spouse’s IRA.